A detailed history of Ubs Asset Management Americas Inc transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 268,203 shares of SRPT stock, worth $29.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
268,203
Previous 301,481 11.04%
Holding current value
$29.7 Million
Previous $47.6 Million 29.67%
% of portfolio
0.01%
Previous 0.01%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$124.33 - $156.75 $4.14 Million - $5.22 Million
-33,278 Reduced 11.04%
268,203 $33.5 Million
Q2 2024

Aug 13, 2024

BUY
$113.33 - $163.85 $15.9 Million - $23 Million
140,454 Added 87.22%
301,481 $47.6 Million
Q1 2024

May 15, 2024

BUY
$93.7 - $141.53 $1,405 - $2,122
15 Added 0.01%
161,027 $20.8 Million
Q4 2023

Feb 14, 2024

SELL
$67.31 - $124.76 $11,442 - $21,209
-170 Reduced 0.11%
161,012 $15.5 Million
Q3 2023

Nov 13, 2023

BUY
$102.5 - $123.59 $460,532 - $555,289
4,493 Added 2.87%
161,182 $19.5 Million
Q1 2023

May 15, 2023

BUY
$117.53 - $155.99 $4.16 Million - $5.52 Million
35,368 Added 29.15%
156,689 $21.6 Million
Q4 2022

Feb 14, 2023

BUY
$100.86 - $132.13 $126,478 - $165,691
1,254 Added 1.04%
121,321 $15.7 Million
Q3 2022

Nov 14, 2022

SELL
$75.71 - $119.24 $1.4 Million - $2.2 Million
-18,440 Reduced 13.31%
120,067 $13.3 Million
Q2 2022

Aug 12, 2022

BUY
$62.69 - $88.44 $60,307 - $85,079
962 Added 0.7%
138,507 $10.4 Million
Q1 2022

May 16, 2022

SELL
$63.15 - $90.42 $1.72 Million - $2.46 Million
-27,201 Reduced 16.51%
137,545 $10.7 Million
Q4 2021

Feb 14, 2022

BUY
$77.28 - $99.42 $4.84 Million - $6.23 Million
62,655 Added 61.37%
164,746 $14.8 Million
Q3 2021

Nov 15, 2021

SELL
$65.97 - $92.48 $635,423 - $890,767
-9,632 Reduced 8.62%
102,091 $9.44 Million
Q2 2021

Aug 16, 2021

SELL
$69.38 - $86.75 $6.47 Million - $8.1 Million
-93,319 Reduced 45.51%
111,723 $8.69 Million
Q1 2021

May 14, 2021

SELL
$72.25 - $168.95 $14.6 Million - $34 Million
-201,513 Reduced 49.57%
205,042 $15.3 Million
Q4 2020

Mar 01, 2021

BUY
$125.56 - $178.74 $1.34 Million - $1.91 Million
10,676 Added 2.7%
406,555 $69.3 Million
Q3 2020

Nov 13, 2020

BUY
$127.12 - $172.34 $43,220 - $58,595
340 Added 0.09%
395,879 $55.6 Million
Q2 2020

Aug 14, 2020

SELL
$93.0 - $171.7 $5.61 Million - $10.4 Million
-60,320 Reduced 13.23%
395,539 $63.4 Million
Q1 2020

May 15, 2020

BUY
$82.38 - $131.64 $361,318 - $577,373
4,386 Added 0.97%
455,859 $44.6 Million
Q4 2019

Feb 14, 2020

BUY
$76.53 - $135.58 $4.47 Million - $7.91 Million
58,372 Added 14.85%
451,473 $58.3 Million
Q3 2019

Nov 14, 2019

BUY
$72.81 - $156.91 $7.03 Million - $15.1 Million
96,536 Added 32.55%
393,101 $29.6 Million
Q2 2019

Aug 15, 2019

BUY
$112.21 - $151.95 $4.74 Million - $6.42 Million
42,263 Added 16.62%
296,565 $0
Q1 2019

May 14, 2019

BUY
$106.67 - $151.68 $1.06 Million - $1.5 Million
9,919 Added 4.06%
254,302 $0
Q4 2018

Feb 13, 2019

BUY
$97.32 - $148.76 $2.07 Million - $3.16 Million
21,262 Added 9.53%
244,383 $26.7 Million
Q3 2018

Nov 14, 2018

BUY
$115.31 - $161.51 $25.7 Million - $36 Million
223,121 New
223,121 $0

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.71B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.